| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Embark | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.55M | Series B | 7/26/2021 | $75M | $759.47M | $16.96 | SoftBank, F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, Third Kind Venture Capital | ||||
 | GATC Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.04M | Series Seed | 7/11/2023 | $4.04M | $500M | $5.60 | Undisclosed Investors | ||||
 | Gravie | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $379M | Series G | 6/5/2026 | $200M | $367.42M | $1.28 | Aberdare Ventures, FirstMark Capital, K2 HealthVentures | ||||
 | Hippocratic AI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $402.92M | Series C | 11/3/2025 | $126M | $3.5B | $26.33 | Avenir Growth, CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children's Hospital, WellSpan Health, John Doerr, Rick Klausner | ||||
 | Latent | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.02M | Series A | 3/18/2026 | $80M | $600M | $0.33 | Spark Capital, Transformation Capital, Conviction, McKesson Ventures, General Catalyst, Y Combinator | ||||
 | Overjet | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.98M | -- | 2 | Not available | -- | -- | $174.12M | Series C-1 | 12/12/2025 | $34.8M | $711.93M | $30.72 | Undisclosed Investors | ||||
 | Parabilis Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $811.88M | Series F | 1/8/2026 | $305.25M | $681.2M | $6.16 | RA Capital Management, Fidelity, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, T. Rowe Price, Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare Investments, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group | ||||
 | Prompt | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $213.08M | Series B | 9/27/2024 | $206M | $929.95M | $248.60 | Undisclosed Investors | ||||
 | SmithRx | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.84M | Series C | 1/23/2024 | $60M | $354.68M | $3.76 | Venrock | ||||
 | Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $100.00K | -- | 1 | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Datavant | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Enveda | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $820.14M | Series E | 9/23/2026 | $311M | $1.83B | $10.38 | -- | ||||
 | Huma | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $137.16M | Series D-1 | 4/4/2024 | $20.25M | $731.49M | $22.88 | Bayer, Touchstone Investment, Ireon Ventures, Minamour Investments | ||||
 | Lyra Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $926.79M | Series G | 1/19/2022 | $235M | $5.58B | $18.23 | Dragoneer, Salesforce Ventures, Coatue | ||||
 | Resilience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.18B | Series D | 6/6/2022 | $625M | $8.84B | $60.73 | Undisclosed Investors | ||||
 | TraceLink | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $278.43M | Series D | 8/21/2018 | $60M | $657M | $16.01 | Georgian Partners, Vulcan Capital, Willett Advisors, FirstMark Capital, Volition Capital, F-Prime Capital, Goldman Sachs | ||||
 | AKASA | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $323.65M | Series D-1 | 7/8/2026 | $55.25M | $968.13M | $32.61 | Undisclosed Investors | ||||
 | Archy | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $96.28M | Series C | 9/11/2026 | $50M | $278.25M | $4.98 | JMI Equity, TCV, Entree Capital, Bessemer Venture Partners, CRV, Alven Capital Partners | ||||
 | Cambrian Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $284.97M | Series D | 6/29/2026 | $95.82M | $357.87M | $2.00 | Undisclosed Investors | ||||
 | Exo | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.94M | Series D | 5/28/2025 | $22.09M | $272.82M | $0.86 | Samsung, Sands Capital, Bold Capital, Qubit Health Capital | ||||
 | Luna | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.17M | Series C-1 | 6/30/2026 | $59.16M | $144.21M | $0.41 | Undisclosed Investors | ||||
 | Medallion | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $136.62M | Series C-1 | 9/2/2026 | $12M | $515.55M | $0.70 | Undisclosed Investors | ||||
 | Noah Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $548.22M | Series B-2 | 9/24/2025 | $111.93M | $571.52M | $4.31 | Undisclosed Investors | ||||